[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613404":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":21,"armGroups":22,"interventions":28,"overallOfficials":17,"centralContacts":33,"locations":43,"responsibleParty":63,"collaborators":17,"id":65,"slug":17,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":17,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":17,"enrollmentInfo":73,"targetDuration":17,"studyType":76,"phases":17,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":46,"whyStopped":17,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Establishment of a biobank of human body material (HBM) and clinical data","Successful prospective collection and long-term storage of blood (serum, plasma, DNA), tissue samples, and associated clinical data from patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.","Baseline (diagnosis and informed consent) through study completion, approximately 10 years.",[14],{"measure":15,"description":16,"timeFrame":12},"Availability of biobank resources for future research","Number of approved satellite protocols using biobank samples and data for translational research.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Adult patients (≥18 years) diagnosed with cutaneous melanoma or non-melanoma skin cancer (including basal cell carcinoma and squamous cell carcinoma) who are treated at University Hospitals Leuven. Participants must provide voluntary written informed consent prior to any study-related procedures. Patients unable or unwilling to provide consent are excluded.",[23],{"label":24,"type":17,"description":25,"interventionNames":26},"Biobank Collection Arm","Participants diagnosed with cutaneous melanoma or non-melanoma skin cancer or healthy controls will provide informed consent for collection and long-term storage of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and associated clinical data for future research.",[27],"Other: Collection of Human Body Material and Clinical Data",[29],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":17},"Collection of Human Body Material and Clinical Data","Blood sampling (serum, plasma, DNA) Tissue sampling (additional biopsy if consented) Completion of Cancer Worry Scale questionnaire",[24],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":17,"email":38},"Annemiek Leeman, Prof. Dr.","CONTACT","0032 016337950","annemiek.leeman@uzleuven.be",{"name":40,"role":36,"phone":41,"phoneExt":17,"email":42},"Sofie Van Kelst, BSc","0032 016337864","sofie.vankelst@kuleuven.be",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"UZLeuven, Department of Dermatology","RECRUITING","Leuven","Vlaams-Brabant","3000","Belgium","BE",{"type":53,"coordinates":54},"Point",[55,56],4.70093,50.87959,{"lat":56,"lon":55},[59,61],{"name":60,"role":36,"phone":41,"phoneExt":17,"email":42},"Sofie Van Kelst, Bsc",{"name":35,"role":62,"phone":17,"phoneExt":17,"email":17},"PRINCIPAL_INVESTIGATOR",{"type":64,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100613404",false,"NCT07266142","Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Adult subjects (\\>18 years of age) at time of enrolment.\n* Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls.\n* Adult subjects able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects unable or not willing to provide informed consent.\n* Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.","ALL","18 Years",{"count":74,"type":75},7500,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.\n\nThe main questions it aims to answer are:\n\n* To create a biobank with samples of human body material (HBM): blood (serum\u002Fplasma\u002FDNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls.\n* To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols).\n\nIf there is a comparison group: Not applicable (umbrella protocol for collection only).\n\nParticipants will:\n\n* Share demographics, medical and surgical history, risk factors.\n* Complete Cancer Worry Scale questionnaire.\n* Provide biological samples:\n\n  * Blood samples (serum, plasma, DNA).\n  * Tissue samples (residual tissue or additional biopsy if consented).",[79,80],"Skin Cancer, Non-Melanoma","Skin Cancer Melanoma",[82,83,84],"Prospective Collection","Skin Cancer","Human Body Material","2026-06-10",{"date":87,"type":88},"2026-06-12","ACTUAL",{"date":90,"type":88},"2025-11-17",{"date":92,"type":75},"2051-01",{"name":5,"class":6},1]